A new murine anti-platelet monoclonal antibody (KOR-P77) has been established and characterized. The specificity of this antibody was examined by indirect immuno fluorescent staining using cultured leukemic cell lines and fresh leukemic cells as target cells.
A BALB/C mouse was immunized intraperitoneally with washed platelets. The spleen cells were fused with myeloma cell lines (NS-1) using polyethylene glycol ac cording to the method of Koler and Milstein. Several hybridoma clones producing anti bodies reactive with platelets were selected and cloned. One of these clones which grew rapidly in liquid culture medium was introduced into the peritoneal space of the BALB/C mouse. Then ascites were obtained and purified. This purified antibody, IgG1, was used for further studies. The antigen recognized by KOR-P77 was analyzed with the affinity chromatography method. Solubilized platelets were applied to the antibody-coupled Sephalose 4B
column. The column-bound proteins were eluted and examined for molecular weight with 10% SDS-PAGE. A 35 kilodalton protein (P77 antigen) was detected by this analysis, which was a platelet-specific antigen different from GP Ib or GP IIb-111a.
V. Reactivity with acute and chronic leukemias ( The distribution of the P77 antigen among fresh leukemic cells was examined. The leukemic cells from acute lymphoblastic leukemia (N=120) and the majority of acute non-lymphocytic leukemia cells (N=39) did not express this antigen. However a small population of mononuclear cells separated from peripheral blood in 5 patients (AML 4, AMoL 1) partially expressed this antigen.
The majority of leukemic cells from all 10 patients with acute megakaryocytic leukemia (AMegL) exhibited this antigen. Leukemic cells from 3 patients among 16 in blast crisis of CML expressed this antigen.
VI. Summary of the patients with leukemic cells expressing P77 antigen (Table 2) In all 10 cases of acute megakaryoblastic leukemia and 3 cases of megakaryoblastic crisis of CML, positive cells composed more than 30% of the blasts. PPO activity was also demonstrated in more than 30% of the blasts in all ten cases (examined (>70% in 8 cases). In cases of AML and AMoL, reactive cells were under 30%. We could not identify whether leukemic cells expressed the P77 antigen or micromegakaryocytes coexisted among leukemic cells.
Among these patients, only 8 children with AMegL were observed. Although AMegL is a very rare leukemia in children, the clinical characteristics were strikingly different from other types of leukemias. The major characteristics were 1) the ages of all patients were under 2 years, often early infancy, and 2) 4 out of 8 patients had accompanying Down's syndrome. 
